Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Triangle Biotechnology
AddedFeb 18, 2024
UpdatedJun 18, 2026
Triangle Biotechnology

Triangle Biotechnology

Triangle Biotechnology: Accelerating research with innovative, high-quality sample prep solutions.

HQ
Chapel Hill, NC, US
Overview
Compare
Fundraising
Employees
Website

Triangle Biotechnology was founded with the mission to accelerate research by providing revolutionary sample preparation solutions. The company focuses on delivering innovative, high-quality, and high-throughput sonication systems for biological sample preparation. Their product offerings include fast, simple, and affordable systems for DNA shearing for next-generation sequencing (NGS), chromatin shearing for chromatin immunoprecipitation (ChIP), and efficient cell lysis methods. Triangle Biotechnology aims to simplify and expedite the sample prep process, making it less time-consuming and more cost-effective for researchers.

Notable affiliated individuals and investors have not been specified, but the company's impact is evident through its key achievements in developing cutting-edge sample prep technologies. Triangle Biotechnology has made significant strides in the life sciences sector by addressing the challenges associated with sample preparation, thereby enhancing research efficiency and productivity. Their innovative solutions have positioned them as a valuable player in the market, contributing to advancements in genomic research and molecular biology.

Triangle Biotechnology - Quick Facts

Where is Triangle Biotechnology's headquarters located?

Triangle Biotechnology's headquarters is located in Chapel Hill, NC, US.

When was Triangle Biotechnology's last funding round?

Triangle Biotechnology's most recent funding round was for $20.3k (USD) in February 2021.

How much has Triangle Biotechnology raised to-date?

As of Feb 2, 2021, Triangle Biotechnology has raised a total of $245.3k (USD).

How many employees does Triangle Biotechnology have?

Triangle Biotechnology has 8 employees as of Feb 4, 2024.

Triangle Biotechnology - Classification

Industry
  • Hardware
Technology
  • Automation
Geographic Exposure
  • Global
Revenue
  • Software
  • Transactional
Customer
  • Enterprise
  • Government
Main Product
  • Sample Preparation
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software